When patients with ovarian carcinoma treated with platinum-based chemotherapy were classified using a two-tier system of expression levels (low or high), the log-rank test revealed that progression-free and overall survival were shorter in patients with highly expressed NAC1 and CARM1 than in those with low expressed proteins (P = 0.0152 and P = 0.0091, respectively) (Figure 3C). The gene discussed is NACC1; the disease is ovarian carcinoma.